Intestinal Research

CrossRef Text and Data Mining

Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.

Real-world data for golimumab treatment in patients with ulcerative colitis in Japan: interim analysis in post-marketing surveillance

Shiro Nakamura, Teita Asano, Hiroaki Tsuchiya, Kanami Sugimoto, Yuya Imai, Seiji Yokoyama, Yasuo Suzuki

Intest Res. 2022;20(3):329-341. Published online August 4, 2021
DOI: https://doi.org/10.5217/ir.2021.00032

Real-world data for golimumab treatment in patients with ulcerative colitis in Japan: interim analysis in post-marketing surveillance

Shiro Nakamura, Teita Asano, Hiroaki Tsuchiya, Kanami Sugimoto, Yuya Imai, Seiji Yokoyama, Yasuo Suzuki

Intestinal Research. 2022;20(3):329-341

Link1

Link2 Link3

P466 Real-world effectiveness and safety of golimumab in patients with ulcerative colitis: 52-weeks of post-marketing surveillance data in Japan

S Nakamura, T Asano, Y Tanaka, K Sugimoto, S Yoshigoe, Y Suzuki

Journal of Crohn's and Colitis. 2022;16(Supplement_1):i439-i441

Link1

Link2

Effectiveness and Safety of Golimumab in the Treatment of Ulcerative Colitis: 52-week Results from Post-marketing Surveillance in Japan

Shiro Nakamura, Teita Asano, Yoshihito Tanaka, Kanami Sugimoto, Shinichi Yoshigoe, Yasuo Suzuki

Inflammatory Intestinal Diseases. 2022;

Link1 Link2

Real-world safety and efficacy of twice-daily budesonide 2-mg foam in patients with ulcerative colitis: interim analysis of post-marketing surveillance

Teppei Omori, Masayuki Saruta, Akira Nagaki, Yuki Arai, Akira Ohta, Kiyotoshi Kuramoto, Yasuo Suzuki

Expert Opinion on Pharmacotherapy. 2021;22(11):1505-1511

Link1

Clinical response among golimumab-treated Japanese patients with rheumatoid arthritis by number of previous biologic therapies: Real-world evidence from post-hoc analysis of post-marketing surveillance data

Hirohito Shimizu, Hisanori Kobayashi, Masayoshi Kanbori, Yutaka Ishii

Modern Rheumatology. 2020;31(3):566-574

Link1

P453 Golimumab in real-world practice in patients with ulcerative colitis: 2-year interim results from a non-interventional trial in Germany

N Teich, H Gruemmer, E Joergensen, T Liceni, W Holtkamp-Endemann, F Cornillie, S Hohenberger, T Fischer

Journal of Crohn's and Colitis. 2019;13(Supplement_1):S337-S338

Link1

P350 Real-world data regarding treatment of ulcerative colitis patients with golimumab in Switzerland

K Perrig, J-B Rossel, L Biedermann, P Schreiner, R Roth, J Zeitz, T Greuter, S Vavricka, N Krupka, P Juillerat, G Rogler, B Misselwitz

Journal of Crohn's and Colitis. 2019;13(Supplement_1):S278-S278

Link1

P433 A real-world observational study assessing treatment persistence in ulcerative colitis patients receiving anti-TNF treatment (golimumab or adalimumab)

S Hoque, S Boccaletti, A Puenpatom, C Brown, C Black, J Roberts, I Rajkovic, G Milligan

Journal of Crohn's and Colitis. 2020;14(Supplement_1):S394-S394

Link1

Link2

Real-world effectiveness of third-line cabazitaxel in patients with metastatic castration-resistant prostate cancer: CARD-like analysis of data from a post-marketing surveillance in Japan

Hideyasu Matsuyama, Nobuaki Matsubara, Hirotaka Kazama, Takeshi Seto, Yoshinori Sunaga, Kazuhiro Suzuki

. 2022;

Link1 Link2

Exam 1: Subcutaneous Golimumab Induces Clinical Response and Remission in Patients With Moderate-to-Severe Ulcerative Colitis and Subcutaneous Golimumab Maintains Clinical Response in Patients With Moderate-to-Severe Ulcerative Colitis

Gastroenterology. 2014;146(1):e14-e15

Link1 Link2